Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.
Identifieur interne : 000532 ( Ncbi/Curation ); précédent : 000531; suivant : 000533Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.
Auteurs : Monika Schoels [Autriche] ; Daniel Aletaha ; Josef S. Smolen ; John B. WongSource :
- Annals of the rheumatic diseases [ 1468-2060 ] ; 2012.
Descripteurs français
- KwdFr :
- Abatacept, Adulte d'âge moyen, Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux d'origine murine (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Essais contrôlés randomisés comme sujet, Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Femelle, Humains, Immunoconjugués (usage thérapeutique), Medline, Mâle, Rhumatisme articulaire aigu (traitement médicamenteux), Rituximab, Résultat thérapeutique, Substitution de médicament, Échec thérapeutique.
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- traitement médicamenteux : Rhumatisme articulaire aigu.
- usage thérapeutique : Anticorps monoclonaux, Anticorps monoclonaux d'origine murine, Anticorps monoclonaux humanisés, Antirhumatismaux, Immunoconjugués.
- Abatacept, Adulte d'âge moyen, Essais contrôlés randomisés comme sujet, Femelle, Humains, Medline, Mâle, Rituximab, Résultat thérapeutique, Substitution de médicament, Échec thérapeutique.
English descriptors
- KwdEn :
- Abatacept, Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antibodies, Monoclonal, Murine-Derived (therapeutic use), Antirheumatic Agents (therapeutic use), Drug Substitution, Female, Humans, Immunoconjugates (therapeutic use), MEDLINE, Male, Middle Aged, Randomized Controlled Trials as Topic, Rheumatic Fever (drug therapy), Rituximab, Treatment Failure, Treatment Outcome, Tumor Necrosis Factor-alpha (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents, Immunoconjugates.
- chemical : Abatacept, Rituximab.
- drug therapy : Rheumatic Fever.
- Drug Substitution, Female, Humans, MEDLINE, Male, Middle Aged, Randomized Controlled Trials as Topic, Treatment Failure, Treatment Outcome.
Abstract
Optimal treatment for rheumatoid arthritis (RA) after inadequate response (IR) to tumour necrosis factor α inhibitors (TNFi) remains uncertain.
DOI: 10.1136/annrheumdis-2011-200490
PubMed: 22294630
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001912
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001912
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001788
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000532
Links to Exploration step
pubmed:22294630Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.</title><author><name sortKey="Schoels, Monika" sort="Schoels, Monika" uniqKey="Schoels M" first="Monika" last="Schoels">Monika Schoels</name><affiliation wicri:level="3"><nlm:affiliation>2nd Department of Internal Medicine, Hietzing Hospital, Vienna, Austria. monika.schoels@chello.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>2nd Department of Internal Medicine, Hietzing Hospital, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Aletaha, Daniel" sort="Aletaha, Daniel" uniqKey="Aletaha D" first="Daniel" last="Aletaha">Daniel Aletaha</name></author><author><name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name></author><author><name sortKey="Wong, John B" sort="Wong, John B" uniqKey="Wong J" first="John B" last="Wong">John B. Wong</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22294630</idno><idno type="pmid">22294630</idno><idno type="doi">10.1136/annrheumdis-2011-200490</idno><idno type="wicri:Area/PubMed/Corpus">001912</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001912</idno><idno type="wicri:Area/PubMed/Curation">001912</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001912</idno><idno type="wicri:Area/PubMed/Checkpoint">001788</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001788</idno><idno type="wicri:Area/Ncbi/Merge">000532</idno><idno type="wicri:Area/Ncbi/Curation">000532</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.</title><author><name sortKey="Schoels, Monika" sort="Schoels, Monika" uniqKey="Schoels M" first="Monika" last="Schoels">Monika Schoels</name><affiliation wicri:level="3"><nlm:affiliation>2nd Department of Internal Medicine, Hietzing Hospital, Vienna, Austria. monika.schoels@chello.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>2nd Department of Internal Medicine, Hietzing Hospital, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Aletaha, Daniel" sort="Aletaha, Daniel" uniqKey="Aletaha D" first="Daniel" last="Aletaha">Daniel Aletaha</name></author><author><name sortKey="Smolen, Josef S" sort="Smolen, Josef S" uniqKey="Smolen J" first="Josef S" last="Smolen">Josef S. Smolen</name></author><author><name sortKey="Wong, John B" sort="Wong, John B" uniqKey="Wong J" first="John B" last="Wong">John B. Wong</name></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="eISSN">1468-2060</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antibodies, Monoclonal, Murine-Derived (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Drug Substitution</term><term>Female</term><term>Humans</term><term>Immunoconjugates (therapeutic use)</term><term>MEDLINE</term><term>Male</term><term>Middle Aged</term><term>Randomized Controlled Trials as Topic</term><term>Rheumatic Fever (drug therapy)</term><term>Rituximab</term><term>Treatment Failure</term><term>Treatment Outcome</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abatacept</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps monoclonaux d'origine murine (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Essais contrôlés randomisés comme sujet</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Femelle</term><term>Humains</term><term>Immunoconjugués (usage thérapeutique)</term><term>Medline</term><term>Mâle</term><term>Rhumatisme articulaire aigu (traitement médicamenteux)</term><term>Rituximab</term><term>Résultat thérapeutique</term><term>Substitution de médicament</term><term>Échec thérapeutique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Antibodies, Monoclonal, Murine-Derived</term><term>Antirheumatic Agents</term><term>Immunoconjugates</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Abatacept</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Rheumatic Fever</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Rhumatisme articulaire aigu</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux d'origine murine</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Immunoconjugués</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Substitution</term><term>Female</term><term>Humans</term><term>MEDLINE</term><term>Male</term><term>Middle Aged</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Failure</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Abatacept</term><term>Adulte d'âge moyen</term><term>Essais contrôlés randomisés comme sujet</term><term>Femelle</term><term>Humains</term><term>Medline</term><term>Mâle</term><term>Rituximab</term><term>Résultat thérapeutique</term><term>Substitution de médicament</term><term>Échec thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Optimal treatment for rheumatoid arthritis (RA) after inadequate response (IR) to tumour necrosis factor α inhibitors (TNFi) remains uncertain.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000532 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000532 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:22294630
|texte= Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:22294630" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |